RU2640913C2 - Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr - Google Patents

Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr Download PDF

Info

Publication number
RU2640913C2
RU2640913C2 RU2014104696A RU2014104696A RU2640913C2 RU 2640913 C2 RU2640913 C2 RU 2640913C2 RU 2014104696 A RU2014104696 A RU 2014104696A RU 2014104696 A RU2014104696 A RU 2014104696A RU 2640913 C2 RU2640913 C2 RU 2640913C2
Authority
RU
Russia
Prior art keywords
ahr
tdo
cells
kyn
inhibitor
Prior art date
Application number
RU2014104696A
Other languages
English (en)
Russian (ru)
Other versions
RU2014104696A (ru
Inventor
Михаель ПЛАТТЕН
Кристиан ОПИТЦ
Вольфганг ВИК
Ульрике ЛИТЦЕНБУРГЕР
Original Assignee
Дойчес Кребсфоршунгсцентрум
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дойчес Кребсфоршунгсцентрум filed Critical Дойчес Кребсфоршунгсцентрум
Publication of RU2014104696A publication Critical patent/RU2014104696A/ru
Application granted granted Critical
Publication of RU2640913C2 publication Critical patent/RU2640913C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11017—Indole 2,3-dioxygenase (1.13.11.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2014104696A 2011-09-07 2012-09-07 Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr RU2640913C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161531861P 2011-09-07 2011-09-07
US61/531,861 2011-09-07
PCT/EP2012/067504 WO2013034685A1 (en) 2011-09-07 2012-09-07 Means and methods for treating and/or preventing natural ahr ligand-dependent cancer

Publications (2)

Publication Number Publication Date
RU2014104696A RU2014104696A (ru) 2015-10-20
RU2640913C2 true RU2640913C2 (ru) 2018-01-12

Family

ID=46832380

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014104696A RU2640913C2 (ru) 2011-09-07 2012-09-07 Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr

Country Status (15)

Country Link
US (1) US9593062B2 (enExample)
EP (1) EP2753315B1 (enExample)
JP (1) JP6047160B2 (enExample)
KR (1) KR20140074330A (enExample)
CN (1) CN104023713A (enExample)
AU (1) AU2012306285B2 (enExample)
BR (1) BR112014004937A2 (enExample)
CA (1) CA2846275C (enExample)
ES (1) ES2626015T3 (enExample)
HK (1) HK1201471A1 (enExample)
IL (1) IL231107A (enExample)
MX (1) MX348941B (enExample)
RU (1) RU2640913C2 (enExample)
WO (1) WO2013034685A1 (enExample)
ZA (1) ZA201401011B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2826628C1 (ru) * 2020-03-27 2024-09-16 Тон-А Ст Ко., Лтд. Производные аминопиримидина и их применение в качестве модуляторов рецептора ароматических углеводородов

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2953065B2 (ja) 1990-12-28 1999-09-27 石川島播磨重工業株式会社 宇宙飛翔体
EP3492094A1 (en) 2013-08-30 2019-06-05 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
EP3186371B1 (en) 2014-08-29 2024-08-14 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
WO2017151860A1 (en) 2016-03-02 2017-09-08 Broard Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
CN107510694B (zh) * 2016-06-16 2022-03-29 中国科学院上海巴斯德研究所 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用
CN106214673A (zh) * 2016-08-31 2016-12-14 深圳市第二人民医院 表没食子儿茶素没食子酸酯在制备预防或治疗膀胱肿瘤的药物中的用途
WO2018085775A1 (en) * 2016-11-04 2018-05-11 Ohio State Innovation Foundation Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor
JP7269917B2 (ja) * 2017-08-17 2023-05-09 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤およびその使用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7432851B2 (ja) 2018-04-16 2024-02-19 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトキヌレニナーゼ酵素及びその使用
RU2699932C1 (ru) * 2018-11-14 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития рака печени у экспериментальных животных
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
JP2023510797A (ja) * 2020-01-10 2023-03-15 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤及びその使用
CN114019164B (zh) * 2020-12-31 2023-11-21 中国科学院生态环境研究中心 筛选抗胶质瘤药物的方法和试剂盒
CN112807305A (zh) * 2020-12-31 2021-05-18 中国科学院生态环境研究中心 Ch223191在抑制肿瘤细胞迁移中的应用
CN114470238A (zh) * 2022-03-25 2022-05-13 华中科技大学同济医学院附属协和医院 AhR抑制剂CH223191在制备抑制肿瘤相关巨噬细胞药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128723A1 (en) * 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg Ah receptor antagonists
US20100183564A1 (en) * 2008-10-30 2010-07-22 Irm Llc Compounds that expand hematopoietic stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
JP4587652B2 (ja) * 2002-09-09 2010-11-24 株式会社フラバミン 新規フラボノイド化合物及びその利用
CN1744887A (zh) * 2003-02-04 2006-03-08 株式会社益力多本社 乳癌耐性蛋白抑制剂
WO2010008427A1 (en) 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128723A1 (en) * 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg Ah receptor antagonists
US20100183564A1 (en) * 2008-10-30 2010-07-22 Irm Llc Compounds that expand hematopoietic stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LYON DE et al. "Tryptophan degradation in women with brest cancer: a pilot study" BMC Res Notes 2011 May 26; 4:156. *
LYON DE et al. "Tryptophan degradation in women with brest cancer: a pilot study" BMC Res Notes 2011 May 26; 4:156. VELDHOEN M. et al. "Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells". J Exp Med. 2009 Jan 16;206(1):43-9. doi: 10.1084/jem.20081438. Epub 2008 Dec 29, реферат, найдено из PubMed PMID:19114668. *
VELDHOEN M. et al. "Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells". J Exp Med. 2009 Jan 16;206(1):43-9. doi: 10.1084/jem.20081438. Epub 2008 Dec 29, , найдено из PubMed PMID:19114668. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2826628C1 (ru) * 2020-03-27 2024-09-16 Тон-А Ст Ко., Лтд. Производные аминопиримидина и их применение в качестве модуляторов рецептора ароматических углеводородов

Also Published As

Publication number Publication date
CA2846275C (en) 2019-07-16
CA2846275A1 (en) 2013-03-14
RU2014104696A (ru) 2015-10-20
ZA201401011B (en) 2018-07-25
IL231107A (en) 2017-11-30
US20140294860A1 (en) 2014-10-02
EP2753315B1 (en) 2017-03-01
ES2626015T3 (es) 2017-07-21
EP2753315A1 (en) 2014-07-16
AU2012306285B2 (en) 2017-05-18
WO2013034685A1 (en) 2013-03-14
BR112014004937A2 (pt) 2017-06-20
MX2014002776A (es) 2014-11-25
JP6047160B2 (ja) 2016-12-21
CN104023713A (zh) 2014-09-03
IL231107A0 (en) 2014-04-30
HK1201471A1 (zh) 2015-09-04
JP2014526450A (ja) 2014-10-06
KR20140074330A (ko) 2014-06-17
MX348941B (es) 2017-07-04
US9593062B2 (en) 2017-03-14
AU2012306285A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
RU2640913C2 (ru) Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr
Zhang et al. FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism
Diedrich et al. Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation
Zhang et al. Effects of propofol on colon cancer metastasis through STAT3/HOTAIR axis by activating WIF‐1 and suppressing Wnt pathway
Zhao et al. RETRACTED: The role and molecular mechanism of Trop2 induced epithelial‐mesenchymal transition through mediated β‐catenin in gastric cancer
Liu et al. Candidate tumour suppressor CCDC 19 regulates miR‐184 direct targeting of C‐Myc thereby suppressing cell growth in non‐small cell lung cancers
JP5651331B2 (ja) 結腸直腸癌の治療におけるプロガストリン阻害剤
Zeng et al. Downregulation of long non‐coding RNA Opa interacting protein 5‐antisense RNA 1 inhibits breast cancer progression by targeting sex‐determining region Y‐box 2 by micro RNA‐129‐5p upregulation
Deng et al. Parathyroid hormone-related protein and ezrin are up-regulated in human lung cancer bone metastases
US11788086B2 (en) Antitumor compounds and tumor diagnosis
JP2019532096A (ja) 腫瘍抑制因子欠損がんを処置するための組成物および方法
Feng et al. KPNA4 regulated by miR-548b-3p promotes the malignant phenotypes of papillary thyroid cancer
Chen et al. PRMT1 potentiates chondrosarcoma development through activation of YAP activity
EP3114233B1 (en) A method for predicting the responsiveness a patient to a treatment with an anti-cd20 antibody
US10626397B2 (en) Therapeutic compositions for breast cancer containing protein kinase D1 inhibitor
Zhang et al. circABCB10 promotes malignant progression of gastric cancer cells by preventing the degradation of MYC
KR20170138955A (ko) 단백질 카이네이즈 d1 저해제를 포함하는 유방암 치료제 조성물
Cheng et al. Downregulation of circ‐RAPGEF5 inhibits colorectal cancer progression by reducing the expression of polypeptide N‐acetylgalactosaminyltransferase 3 (GALNT3)
KR102181813B1 (ko) 단백질 카이네이즈 d1 저해제를 포함하는 유방암 치료제 조성물
Zhou et al. Knockdown of the long non-coding RNA CACNA1G-AS1 enhances cytotoxicity and apoptosis of human diffuse large B cell lymphoma by regulating miR-3160-5p
Qian et al. PFOA exposure promotes prostate cancer progression by enhancing autophagy through m6A modification of MAPK15 mRNA
Wang et al. A positive feedback loop between TAZ and miR-942-3p modulates proliferation, migration, epithelial-mesenchymal transition process and glycometabolism in human bladder cancer
Peng Exon 3-Deleted FOXP3 Isoform in Non-Small Cell Lung Cancer
Guo et al. UBE2C Directly Targeted by mirR-548-5p Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein ZEB1/2 in NSCLC
Lv et al. The Fusion Circular RNA F-circEA1 Promotes Non-small Cell Lung Carcinoma Progression through ALK Downstream Signaling